Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
21 mai 2020 07h00 HE
|
Imara, Inc.
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports First Quarter 2020 Financial Results and Business Highlights
07 mai 2020 07h00 HE
|
Imara, Inc.
Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in sickle cell disease and...
Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
06 mai 2020 07h00 HE
|
Imara, Inc.
BOSTON, May 06, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces Appointment of Stephen M. Migausky as General Counsel
04 mai 2020 07h00 HE
|
Imara, Inc.
BOSTON, May 04, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.
23 avr. 2020 07h00 HE
|
Imara, Inc.
Industry leader with global clinical development expertise to help guide Imara’s clinical advancement Imara also announces departure of Chief Medical Officer, Willem Scheele BOSTON, April 23, 2020 ...
IMARA Announces Pricing of Initial Public Offering
11 mars 2020 21h57 HE
|
Imara, Inc.
BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...